Citations

Clear

590 citation(s) found for "Ho, Ben".

At-Home Transvaginal Pelvic Ultrasonography and Image Quality in Premenopausal Women
Sacha, Caitlin, Doke, Ben, Vitek, Wendy, Fridman, Dmitry , Islam, Tina, Pecoriello, Jillian, Chelliah, Jerome, Martini, Annie, Verrilli, Lauren, Brown, Michelle, Styer, Aaron, Ainsworth, Alessandra J. , Vagios, Stylianos , Vitek, Wendy , Pecoriello, Jillian M. , Verrilli, Lauren Elizabeth , Styer, Aaron Kyle

Mayo Clinic

JAMA Network Open | July 6, 2026 | Volume: 9 | Issue: 7 | Pages: e2621476

10.1001/jamanetworkopen.2026.21476 | PMID 42406404 Get It

Importance Transvaginal pelvic imaging is an integral and sensitive aspect of gynecologic care that individuals find both invasive and burdensome. At-home transvaginal imaging provides an opportunity to navigate these barriers to care. Objective To evaluate the use of at-home transvaginal ultrasonography for gynecologic assessment, as measured by diagnostic imaging quality and participant satisfaction, in a broad sampling of women aged 22 to 50 years. Design, Setting, and Participants Prospective, interventional, single group nonrandomized clinical trial with blinded review of collected images from premenopausal women aged 22 to 50 from Florida, Massachusetts, Maryland, Maine, Minnesota, New Hampshire, Texas, Utah, Virginia, Vermont, and Washington, DC. Images were gathered between July 2022 and July 2023, and data were analyzed from April to September 2025. Intervention At-home pelvic ultrasonography guided by verbal communication with a fully trained remote sonographer who had real-time access to study images. Cine clips were used to capture standard views of the uterus, ovaries, cervix, and posterior cul-de-sac. Main Outcomes and Measures Primary outcomes were image quality and participant net promoter score (NPS), reflecting participants' likelihood of recommending the procedure, with higher scores indicating greater likelihood. Secondary outcomes included minor pain or discomfort, sonographer reported experience and/or pain, and all other adverse events. Results A total of 265 participants (mean [SD] age, 32 [6.7] years; mean [SD] body mass index, 27.0 [5.6]) enrolled in the trial, and 263 ultrasonographic scans were completed. Image quality showed that 253 at-home ultrasonographic scans (96.2%) met diagnostic quality while 10 (3.8%) did not. NPS was significantly higher with use of the at-home ultrasonography (59) compared with in-clinic scans (24), with an adjusted difference of 33.7 (95% CI, 23.3-44.0; z = 6.35; P < .001). No adverse events were reported. Conclusions and Relevance This nonrandomized clinical trial of at-home pelvic ultrasonography in premenopausal women demonstrated that broad use of at-home gynecologic ultrasonography technology is feasible, safe, and preferred by participants and sonographers compared with in-clinic ultrasonography. At-home ultrasonographic imaging presented an innovative and clinically acceptable alternative to in-clinic care, providing opportunities for improved access to and decreased burden of gynecologic and reproductive care. Registration ClinicalTrials.gov NCT05443698
Association of Sleep Duration Ratio with a Reduced Risk of Heart Failure: Analysis of the 2017–2023 National Health and Nutrition Examination Survey
Kulthamrongsri, Narathorn , Suenghataiphorn, Thanathip , Sripusanapan, Adivitch , Siramongkholkarn, Smuch , Srikulmontri, Thitiphan , Puchongmart, Chanokporn , Thiravetyan, Ben , Ngarmukos, Kridhitach, Lorlowhakarn, Koravich , Tangprasittichok, Nathasith , Nuqali, Abdulelah, Tantisattamo, Ekamol , Suenghataiphorn, Thanathip , Yinadsawaphan, Thanaboon , Thiravetyan, Ben , Ngarmukos, Kridhitach , Tangprasittichok, Nathasith , Tantisattamo, Ekamol , Kulthamrongsri, Narathorn

Mayo Clinic

Journal of Clinical Medicine | June 30, 2026 | Volume: 15 | Issue: 13 | Pages: 5047

10.3390/jcm15135047 | PMID 42452509 Get It

Background/Objectives: In the United States, HF prevalence is projected to progressively rise by 2030. Prior research suggests a strong association between reduced sleep duration and increased cardiovascular disease and HF risk. This study introduces an alternative parameter, the weekend sleep recovery (WSR), measured by the weekend-to-weekday sleep duration ratio (SDR), to evaluate its association with HF risk. Methods: We conducted a cross-sectional analysis of NHANES (National Health and Nutrition Examination Survey) 2017–2023 to examine self-reported sleep patterns. Participants were classified as WSR (SDR > 1) or non-WSR (SDR ≤ 1). Multivariate logistic regression assessed the association between WSR and HF, adjusting for demographics and comorbidities. Results: Among 8320 participants included in the fully adjusted analysis, WSR was associated with lower odds of HF compared with non-WSR (adjusted OR 0.73, 95% CI 0.55–0.96; p = 0.026). A significant interaction was observed between WSR and weekday sleep duration (P for interaction = 0.003), whereas no interaction was found with weekend sleep duration. In exploratory subgroup analyses, nominally significant associations were observed in several clinical subgroups; however, after correction for multiple comparisons, only participants without dyslipidemia retained statistical significance. No significant effect modification by race/ethnicity was observed (P for interaction = 0.436). Conclusions: Weekend sleep recovery was associated with lower odds of HF in this cross-sectional study. The association varied according to weekday sleep duration but was generally consistent across racial/ethnic groups. Given the observational design, these findings should be interpreted as associative rather than causal and warrant confirmation in prospective studies.
Clinical impact of renal function deterioration while awaiting heart transplantation in patients bridged with left ventricular assist devices: a multicenter analysis of the UNOS database
Asleh, R, Kushwaha, S, Khalil, F, Regev, O, Briasoulis, A, Alnsasra, H, Asleh, Rabea , Kushwaha, S.S., Khalil, Fouad , Regev, O, Briasoulis, Αlexandros , Alnsasra, Hilmi

Mayo Clinic

European Journal of Heart Failure | June 29, 2026 | Volume: 28 | Issue: Supplement_2 | Pages: No page available

10.1093/ejhf/xuag193.650 Get It

Abstract Background Renal dysfunction is a major determinant of outcomes after heart transplantation (HT). While baseline renal impairment and post-HT dialysis are known predictors of mortality, the prognostic impact of sustained pre-HT renal decline in patients bridged with durable left ventricular assist devices (LVADs) remains unclear. Methods We conducted a retrospective, multicenter cohort study using the United Network for Organ Sharing (UNOS) registry to identify adult patients who underwent HT following durable LVAD support between 2009 and 2024. Sustained renal decline was defined as a ≥40% reduction in estimated glomerular filtration rate (eGFR) from listing to HT. Multivariable logistic regression identified predictors of renal decline and post-HT dialysis,while Cox proportional hazards models assessed the impact on post-HT mortality. Results Among 10,454 eligible patients, 624 (6.0%) experienced sustained renal decline during LVAD bridging. Compared with patients without renal decline, affected patients had longer waitlist durations (median 297 vs. 197 days; p<0.001), lower eGFR at HT (42.0 vs. 70.6 mL/min/1.73 m²; p<0.001), and higher rates of post-HT dialysis (23.7% vs. 12.8%; p<0.001). Independent predictors of sustained renal decline included longer waitlist time, perioperative blood transfusions, while the use of HeartMate 3 LVAD was protective. Sustained renal decline was independently associated with increased risk of post-HT dialysis (adjusted odds ratio [aOR] 2.64) and all-cause mortality (adjusted hazard ratio [aHR] 1.16),with post-HT dialysis strongly predicting mortality (aHR 3.48). Conclusions Sustained renal deterioration while awaiting HT is a significant predictor of post-HT dialysis and mortality in LVAD-bridged patients. Incorporating renal trajectory into risk stratification may enhance candidate selection and promote perioperative renal protection strategies.
P412 Worldwide prevalence of appendectomy and its association with disorders of gut-brain interaction
Simadibrata, Daniel M, Lamichhane, Ramesh , Al-Fakhouri, Zaid , Alomari, Laith, Cheng, Kueh Yee , Palsson, Olafur S, Sperber, Ami D, Bangdiwala, Shrikant I, Butt, Mohsin F. , Simadibrata, Daniel Martin , Alomari, Laith , Palsson, Olafur S. , Sperber, Ami D , Bangdiwala, Shrikant I. , Lee, Yeong Yeh

Mayo Clinic

E-Posters | June 23, 2026 | Volume: No volume available | Issue: No issue available | Pages: A330-A331

10.1136/gutjnl-2026-bsg.517 Get It

Mechanosensitive Piezo Channels Contribute to Airway Changes in Chronic Obstructive Pulmonary Disease
Migulina, Nataliya , Roos, Benjamin, Borghuis, Theo, Ngassie, Maunick Lefin Koloko , Drake, Li Y. , Timens, Wim , Vogel, Elizabeth R. , Pabelick, Christina M. , Roos, Ben, Koloko Ngassie, Maunick Lefin , Drake, Li , Brandsma, Corry-Anke , Burgess, Janette K , Prakash, Y S , Pabelick, Christina M , Vogel, Elizabeth R , Timens, Wim , Roos, B., Brandsma, Corry‐Anke , Burgess, Janette K. , Prakash, Y. S.

Mayo Clinic

No container title available | June 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.06.14.732150 | PMID 42367887 Get It

Abstract As an intrinsically mechanosensitive organ, the lung experiences a range of mechanical forces. Chronic obstructive pulmonary disease (COPD) involves abnormal macroscopic cellular and extracellular matrix (ECM) changes that impact mechanical properties of the lung. Mechanosensitive Piezo1/2 channels are expressed in the lung including on airway smooth muscle cells (ASM) that mediate cellular responses to stretch and ECM biomechanics. The expression and roles of Piezos in COPD lung ASM are not known. We hypothesized that Piezo expression and activation are altered in COPD lung ASM influencing ECM regulation. Distribution of Piezo proteins in ASM and epithelium of small airways of COPD stage II and IV vs. non-COPD controls was assessed using immunohistochemistry and ImageJ (n=10-17/group). Isolated ASM cells from control (n=6) vs. COPD stage II and IV patients (n=3 each stage) were exposed to stretch or the Piezo1 agonist Yoda1 followed by measurement of ECM gene and protein expression. Less Piezo2 staining was observed in COPD IV patients compared to controls, with lesser area and intensity of staining in the epithelial layer, and lower intensity of staining in ASM and small airways as a whole. Fura-2-based imaging of ASM Ca 2+ showed lower influx after Yoda1 exposure in COPD II compared to control and COPD IV. Gene expression of Piezo1 increased upon stretching in controls but not in COPD ASM, while Piezo2 protein expression decreased with stretching in all groups. Yoda1 treatment resulted in decreased collagen1 , fibulin1 and periostin gene and collagen 1 and periostin protein expression in ASM. Overall, these results support a role for Piezo activation in abnormal ECM-ASM cell crosstalk in COPD.
Defining Success and Failure In Prosthetic Joint Infections: A Meta-epidemiologic Study Toward A Core Outcome Set
Petri, Francesco , Alavi, Seyed Mohammad Amin , Ciubotariu, Cosmin Lucian , Borgonovo, Fabio , Matsuo, Takahiro , Khawar, Haseeb, Marson, Ben A. , Jagtiani, Anil, Murad, M. Hassan , Gori, Andrea, Berbari, Elie F. , Passerini, Matteo , Borgonovo, Fabio , Matsuo, Takahiro , Khawar, Haseeb , Marson, Ben A , Murad, M Hassan , Gori, Andrea , Tande, Aaron , Petri, Francesco , Alavi, Seyed Mohammad Amin , Ciubotariu, Cosmin Lucian , Passerini, Matteo

Mayo Clinic

Open Forum Infectious Diseases | June 17, 2026 | Volume: 13 | Issue: 7 | Pages: No page available

10.1093/ofid/ofag364 | PMID 42388828 Get It

Abstract Background Prosthetic joint infection (PJI) represents an important complication of total joint arthroplasty, affecting approximately 2% of patients. However, considerable heterogeneity in outcome definitions renders cross-study and clinical comparisons challenging. Methods We performed a meta-epidemiological study and systematic review of cohort studies and randomized controlled trial (RCTs) reporting clear definitions of PJI outcomes. Relevant data regarding outcome definitions of treatment success or failure were extracted and categorized into 7 outcome domains: clinical signs and symptoms, imaging, microbiology, mortality, antibiotics-related, surgical-related, and histology. A network plot was generated to visualize domains combinations. Data on patient-reported outcome measures (PROMs) were also collected. Based on these results, we finally proposed a working definition of PJI core outcome set. Results The literature search identified 7585 references, leading to 461 studies. The majority were retrospective (416/461, 90.2%), with limited representation of prospective studies (37/461, 8.0%) and RCTs (8/461, 1.7%). Outcome reporting was highly heterogeneous, with the clinical criterion being the most frequently used domain, combined with microbiological, surgical, and mortality-related outcomes. In contrast, histopathological, imaging, and antibiotic-related criteria were rarely reported. Thirty-six PROMs were included in only 111 (24.1%) studies, most commonly the Knee Society Score (26%) and Harris Hip Score (23%). Conclusions We showed substantial heterogeneity in PJI outcome definitions, with inconsistent reporting across key domains, limiting comparability and evidence synthesis. Standardized, consensus-based outcomes incorporating patient-reported and antibiotic-related measures are needed, and the proposed core outcome set may support harmonized research and clinical practice aligned with the new PJI definition.
BMS-986504 in patients (pts) with advanced solid tumors with homozygous MTAP deletion ( MTAP -del): Exploratory pharmacodynamic (PD) and biomarker analyses from C
Henry, Jason T. , Perumal, Deepak, Ahnert, Jordi Rodon, George, Ben, Jänne, P A, Leventakos, Konstantinos, Arbour, Kathryn C., Haddox, Candace L., Spira, A, Perez, C., Zuniga, Richard, Qin, Yidi, Hung, Amy, Abaskharoun, Mena, Lei, Ming, George, Ben , Jänne, Pasi A. , Arbour, Kathryn C. , Johnson, Melissa L. , Papadopoulos, Kyriakos, Haddox, Candace L. , Spira, Alexander I. , Perez, Cesar A. , Babiker, Hani M. , Zuniga, Richard, Kamgar, Mandana , Kumar, Tapsi , Lei, Ming

Mayo Clinic

Journal of Clinical Oncology | May 27, 2026 | Volume: 44 | Issue: 16_suppl | Pages: 3146-3146

10.1200/jco.2026.44.16_suppl.3146 Get It

3146 Background: The MTA-cooperative PRMT5 inhibitor BMS-986504 selectively binds to the PRMT5-MTA complex, a synthetic lethal target in MTAP -del cancer cells, while sparing MTAP –wild-type normal cells. In the phase 1 CA240-0007 study, BMS-986504 was well tolerated and had antitumor activity in pts with MTAP -del advanced solid tumors (ORR, 23%; median DOR, 10.5 mo). BMS-986504 also demonstrated dose-dependent reductions in plasma symmetric dimethylarginine (SDMA) levels, a PD biomarker of PRMT5 inhibition. Here, we report expanded PD and genomic analyses and initial results of exploratory proteomic analyses from CA240-0007. Methods: Pts with advanced, unresectable, or metastatic solid tumors with homozygous MTAP -del received BMS-986504 (50–800 mg) in 3-wk cycles. Analyses of SDMA levels and proteomic profiles from paired plasma samples (baseline and C2D1) were performed using mass spectrometry and SomaScan 11K, respectively. Tumor genomic information was extracted from local pathology reports. ORR was assessed per RECIST v1.1. Results: Among 78 pts with paired samples at data cutoff (22 Sept 2025; median f/u, 15.9 mo), dose-dependent reductions were seen in plasma SDMA levels, with the greatest reductions at 400 mg QD (median, 60.3%; n = 31) and 600 mg QD (median, 60.3%; n = 23). Proteomic pathway enrichment analysis demonstrated downregulation of PI3K/Akt/mTOR, Myc target, cell cycle, and DNA damage repair (DDR) pathways with BMS-986504 on C2D1 (n = 87), consistent with the expected effect of PRMT5 inhibition; a trend toward deeper modulation of PRMT5-regulated pathways was observed at higher doses. No proteins at baseline (n = 94) were found to be significantly associated with ORR (false discovery rate > 0.05). Responses in clinically evaluable pts with NSCLC (n = 33) or PDAC (n = 35) were observed regardless of EGFR , KRAS , or TP53 status. In pts with NSCLC, STK11 and SMARCA4 alterations were numerically higher in nonresponders. No gene alterations were associated with response in PDAC, except GABRA6 alterations (n = 2, both responders). A trend toward higher ORRs was seen in pts with alterations in DDR genes ( CHEK2, FANCD2, XRCC4 , and/or MSH2 ), consistent with the role of PRMT5 in DDR via regulation of mRNA splicing. ctDNA analysis will be presented. Conclusions: BMS-986504 demonstrated robust dose-dependent PD effects in pts with advanced solid tumors in plasma SDMA and proteomic analyses. Downregulation of PRMT5-regulated pathways was observed with BMS-986504 treatment. Response was seen regardless of EGFR, KRAS , and TP53 alterations in NSCLC or PDAC, and DDR gene alterations were associated with improved response. These findings further support the MOA of BMS-986504 and its ongoing investigation in the phase 2/3 MountainTAP-9, -29, and -30 studies as a potential treatment option in pts with MTAP -del advanced solid tumors. Clinical trial information: NCT05245500 .
Optimizing Radiography Utilization: Multidisciplinary Expert Consensus Recommendations Endorsed by the Society of Academic Bone Radiologists, Society of Skeletal Radiology, American Society of Emergency Radiology,
Rilland, Eddy D. Zandee van , Fayad, Laura M. , Link, Thomas M. , Davis, Kirkland W. , Wu, Jim S. , Chang, Eric Y. , Chow, Lawrence C. , Desai, Shaun C., Fritz, Jan, Gorbachova, Tetyana , Gray, Mingyang L., Gross, Joel A. , Ha, Patrick K., Halle, Tyler R. , Hall, M. Kennedy, Lee, Mark A. , Mann, Edana D. , Obey, Mitchel R. , Osgood, Greg M., Patel, Zara M. , Rendon, Juan M. , Sabbatini, Amber K. , Tannoury, Chadi , Yu, Joseph S. , Boutin, Robert D. , Zandee van Rilland, Eddy D , Brown, Ian P , Chang, Eric Y , Chow, Lawrence C , Gatz, J David , Garner, Hillary W , Gorbachova, Tetyana , Guermazi, Ali , Halle, Tyler R , Hanna, Tarek N , Kornblith, Aaron E , Lopez-Ben, Robert R , Mann, Edana D , Moore, Christopher L. , Obey, Mitchel R , Patel, Zara , Raja, Ali S , Rendon, Juan M , Sabbatini, Amber K , Tannoury, Chadi , Yu, Joseph S , Boutin, Robert D , Link, Thomas M , Desai, Shaun C. , Fritz, Jan , Garner, Hillary W. , Gray, Mingyang Liu , Hall, M. Kennedy , Osgood, Greg Michael

Mayo Clinic

Radiology | May 19, 2026 | Volume: 319 | Issue: 2 | Pages: No page available

10.1148/radiol.252309 | PMID 42153836 Get It

Expert consensus recommendations from 21 academic centers were established for appropriate radiography utilization at 12 potentially low-yield anatomic sites through a multidisciplinary process endorsed by six major American medical societies.
Preloaded vs manually loaded intraocular lens delivery failure modes: an analysis of Food and Drug Administration device reports
Sella, Ruti , Hecht, Idan , Tuuminen, Raimo , Kanclerz, Piotr

Mayo Clinic

Journal of Cataract & Refractive Surgery | May 19, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/j.jcrs.0000000000001977 | PMID 42153648 Get It

Purpose: To compare reported intraoperative failure-mode profiles between preloaded and manually loaded intraocular lens (IOL) delivery systems using U.S. Food and Drug Administration (FDA) device reports. Setting: FDA Manufacturer and User Facility Device Experience (MAUDE) database, United States. Design: Retrospective cross-sectional study. Methods: MAUDE reports from January 1, 2016 through December 31, 2025 were reviewed. Reports describing intraoperative IOL loading, delivery, or positioning issues were included when injector type was specified. Structured MAUDE fields served as the primary data source, and free-text narratives were analyzed using automated natural language processing to supplement classification when consistent with structured fields. Comparisons were performed using within-group proportions, and multivariable logistic regression estimated adjusted odds ratios (aORs) controlling for report year, manufacturer, lens platform, and reporting entity. Results: Of 57,435 FDA device reports, 14,460 intraoperative reports met inclusion criteria; 10,567 (73.1%) involved preloaded systems and 3,893 (26.9%) manually loaded systems. Manually loaded systems showed higher reporting of IOL damage (66.0% vs 45.4%; aOR 3.06, 95% CI 2.78–3.37; p<0.001) and loading issues (aOR 5.53, 95% CI 3.99–7.66; p<0.001). Preloaded systems showed higher reporting of delivery failures (40.5% vs 21.8%; aOR 3.91, 95% CI 3.51–4.35; p<0.001), lens positioning issues (aOR 1.27, 95% CI 1.01–1.62; p=0.041), and material or optics abnormalities (aOR 3.53, 95% CI 1.96–6.35; p<0.001). Conclusions: Preloaded and manually loaded IOL delivery systems demonstrated distinct failure-mode profiles within FDA device reports. These findings characterized reporting patterns rather than population-level risk and may inform device design and post-market surveillance priorities.
First in human evidence of autonomically-mediated immune dysfunction after spinal cord injury
Solinsky, Ryan, Hareland, Kimberly, Veith, Daniel, Overlee, Brittany, Shang, Pei , Clarkson, Ben, Howe, Charles, Solinsky, Ryan , Veith, Daniel D. , Overlee, Brittany L., Howe, Charles L.

Mayo Clinic

Physiology | May 12, 2026 | Volume: 41 | Issue: S1 | Pages: No page available

10.1152/physiol.2026.41.s1.2345659 Get It

Study objective: To characterize physiologic autonomic dysfunction in humans after chronic spinal cord injury (SCI) relative to uninjured controls and to identify autonomic correlates to neuroimmune deficits. Hypothesis: Individuals with greater autonomic dysfunction after SCI will have more pronounced immune dysfunction, which will be further influenced by sympathetically mediated increases in catecholamine levels. Methodology: Both uninjured controls and individuals with SCI completed a battery of autonomic physiology tests aimed at characterizing preservation of supralesional/sublesional sympathetic activation and global sympathetic inhibition. The autonomic testing battery included 3-minute hand and foot cold pressor tests, 3 Valsalva maneuvers with goal expiratory pressure of 30 mmHg, a novel bladder pressor test (5 minutes of sustained bladder pressure at 35 cmH20 with room temperature sterile water infusion), paced breathing at 0.25 Hz for heart rate/blood pressure variability, and successive doses of bolus intravenous phenylephrine (Oxford technique). A subset of individuals in both cohorts had baseline and cold pressor stressed levels of catecholamines/cortisol drawn and immunologic assessments. Peripheral blood mononuclear cells were extracted from this baseline sample and assessed with flow cytometry for cellular exhaustion markers (CD69, PD-1, TIGIT, TIM-3). Antigen recall response, with/without primed exposure of catecholamines was also completed to identify how sympathetic activation variably impacted functional immune performance with exposure to viral peptides. Data: n=35 uninjured controls; n=29 individuals with SCI Summary of Results: When compared to uninjured controls, individuals with SCI demonstrated significant autonomic dysfunction in all three domains, with decreased supralesional sympathetic activation (Valsalva pressure recovery time, p< 0.0001), abnormal sublesional sympathetic activation (increased bradycardia, p< 0.0001), and impaired sympathetic inhibition (larger dose/body-weight adjusted increase in mean arterial pressure, p=0.0006). As expected, autonomic dysfunction in those with SCI existed on a continuum, with some having largely normal autonomic regulation and others exhibiting profound deficits. Principal component analysis confirmed these three domains as the primary drivers of variability. Cellular exhaustion markers were increased in those with SCI, with positive correlation (R2=0.42) between degree of global autonomic dysfunction (Z-score over 2.0) and CD3+ CD8+ T-cell TIM-3 immunologic exhaustion markers. Antigen recall response was impaired in those with SCI and autonomic dysfunction on physiologic testing, with pronounced decrement in response when catecholamines were added (mean 57% of response lost in CD69 T-cells to Epstein-Barr virus antigen exposure, 53% lost to Flu antigen). Conclusions: In humans with SCI, early evidence supports that individuals have greater autonomic dysfunction and that this is correlated to increased immunologic deficits. Funding Sources: NIH K23HD102663, R01NS115126 This abstract was presented at the American Physiology Summit 2026 and is only available in HTML format. There is no downloadable file or PDF version. The Physiology editorial board was not involved in the peer review process.